Free Trial
NASDAQ:NBRV

Nabriva Therapeutics (NBRV) Stock Price, News & Analysis

Nabriva Therapeutics logo

About Nabriva Therapeutics Stock (NASDAQ:NBRV)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
29,344 shs
Market Capitalization
$45.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NBRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NBRV Stock News Headlines

Nabriva Therapeutics plc (NBRVF)
Nabriva Therapeutics PLC NBRVF
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
NBRV - Nabriva Therapeutics plc
NBRV Nabriva Therapeutics plc
Nabriva Therapeutics Provides Corporate Update
See More Headlines

NBRV Stock Analysis - Frequently Asked Questions

Nabriva Therapeutics plc (NASDAQ:NBRV) released its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($13.25) EPS for the quarter, topping the consensus estimate of ($16.75) by $3.50. The biotechnology company earned $2.53 million during the quarter, compared to the consensus estimate of $2.25 million. Nabriva Therapeutics had a negative net margin of 148.11% and a negative trailing twelve-month return on equity of 365.53%.

Nabriva Therapeutics shares reverse split on Friday, September 16th 2022.The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nabriva Therapeutics investors own include SCYNEXIS (SCYX), Vaxart (VXRT), VBI Vaccines (VBIV), Acasti Pharma (ACST), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Dynavax Technologies (DVAX).

Company Calendar

Last Earnings
5/06/2021
Today
8/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NBRV
CIK
1641640
Employees
70
Year Founded
2001

Profitability

EPS (Trailing Twelve Months)
($19.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$57.19 million
Net Margins
-148.11%
Pretax Margin
-144.78%
Return on Equity
-365.53%
Return on Assets
-135.81%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
0.85
Quick Ratio
0.52

Sales & Book Value

Annual Sales
$35.59 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.10 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
32,015,000
Free Float
31,493,000
Market Cap
$45.46 million
Optionable
Not Optionable
Beta
1.53

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:NBRV) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners